Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

Fig. 3

Correlation analysis of serum SV2A with other biomarkers, and the diagnostic efficiency of serum SV2A combined with these biomarkers in aMCI and AD. Relationship of serum SV2A with (a) serum GFAP, (b) serum p-tau217, and (c) serum NfL. d. Diagnostic efficiency of serum NfL, GFAP, and p-tau217 in Con vs. aMCI. e. Diagnostic efficiency of serum NfL, GFAP, and p-tau217 in Con vs. AD. f. Diagnostic efficiency of serum NfL, GFAP, and p-tau217 in aMCI vs. AD. g. Diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in Con vs. aMCI. h. Diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in Con vs. AD. i. Diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in aMCI vs. AD. Correlation analysis was performed using Spearman’s rank correlation coefficient. Abbreviations: AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AUC, area under the curve; Con, healthy control; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p-tau217, phosphorylated tau; SV2A, synaptic vesicle glycoprotein 2 A; vs., versus

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193